Author + information
- Received August 24, 2011
- Revision received October 19, 2011
- Accepted November 22, 2011
- Published online March 6, 2012.
- Tao-Sheng Li, MD, PhD⁎,†,
- Ke Cheng, PhD⁎,
- Konstantinos Malliaras, MD⁎,
- Rachel Ruckdeschel Smith, PhD⁎,‡,
- Yiqiang Zhang, PhD⁎,
- Baiming Sun, MD⁎,
- Noriko Matsushita, MD, PhD⁎,
- Agnieszka Blusztajn, BS‡,
- John Terrovitis, MD§,
- Hideo Kusuoka, MD, PhD∥,
- Linda Marbán, PhD⁎,‡ and
- Eduardo Marbán, MD, PhD⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Eduardo Marbán, Cedars-Sinai Heart Institute, 8700 Beverly Boulevard, Los Angeles, California 90048
Objectives The goal of this study was to conduct a direct head-to-head comparison of different stem cell types in vitro for various assays of potency and in vivo for functional myocardial repair in the same mouse model of myocardial infarction.
Background Adult stem cells of diverse origins (e.g., bone marrow, fat, heart) and antigenic identity have been studied for repair of the damaged heart, but the relative utility of the various cell types remains unclear.
Methods Human cardiosphere-derived cells (CDCs), bone marrow–derived mesenchymal stem cells, adipose tissue–derived mesenchymal stem cells, and bone marrow mononuclear cells were compared.
Results CDCs revealed a distinctive phenotype with uniform expression of CD105, partial expression of c-kit and CD90, and negligible expression of hematopoietic markers. In vitro, CDCs showed the greatest myogenic differentiation potency, highest angiogenic potential, and relatively high production of various angiogenic and antiapoptotic-secreted factors. In vivo, injection of CDCs into the infarcted mouse hearts resulted in superior improvement of cardiac function, the highest cell engraftment and myogenic differentiation rates, and the least-abnormal heart morphology 3 weeks after treatment. CDC-treated hearts also exhibited the lowest number of apoptotic cells. The c-kit+ subpopulation purified from CDCs produced lower levels of paracrine factors and inferior functional benefit when compared with unsorted CDCs. To validate the comparison of cells from various human donors, selected results were confirmed in cells of different types derived from individual rats.
Conclusions CDCs exhibited a balanced profile of paracrine factor production and, among various comparator cell types/subpopulations, provided the greatest functional benefit in experimental myocardial infarction.
It is now recognized that resident cardiac stem cells exist in the adult mammalian heart, including mouse, rat, and human (1–7). Several groups have expanded the small population of cardiac stem cells from adult human heart tissue with a view to clinical applications in regenerative therapy (7–9). We have developed a technique to expand tens of millions of cardiosphere-derived cells (CDCs), a mixture of cardiac stem cells and supporting cells, from percutaneous endomyocardial biopsies (8). This technology is in Phase I clinical study for the treatment of post-ischemic heart failure (CADUCEUS [Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction; NCT00893360]). Nevertheless, heart-derived cells are relative newcomers to regenerative cardiology.
Multiple extracardiac cell sources, including bone marrow mononuclear cells (BM-MNCs), bone marrow–derived mesenchymal stem cells (BM-MSCs), adipose tissue–derived mesenchymal stem cells (AD-MSCs), endothelial progenitor cells, and myoblasts, have been used clinically in attempts to regenerate the damaged heart (10–18). The implantation of these cells of extracardiac origin has been found to produce generally positive effects, mostly through paracrine mechanisms (19–22). Although resident cardiac stem cells can mediate direct cardiogenesis and angiogenesis (1–7,23,24), recent studies have found that even these cells exert most of their benefits via indirect paracrine mechanisms (25,26). Therefore, no convincing evidence supports the superiority of heart-derived cells for myocardial repair. Even within heart-derived cells, 2 cell products are in clinical trials, but these have yet to be compared directly. The first, CDCs, are a natural mixture of stromal, mesenchymal, and progenitor cells (8); the second cell product represents the c-kit+ subpopulation purified from mixed heart-derived cells (1,9).
In the current study, we performed a head-to-head comparison of different stem cell types/subpopulations for functional myocardial repair by assessing multiple in vitro parameters, including secretion of relevant growth factors, and in vivo cell implantation into an acute myocardial infarction model in severe combined immunodeficiency (SCID) mice.
Human CDCs were expanded as previously described from minimally invasive endomyocardial biopsies (27). Human BM-MSCs and BM-MNCs were purchased from Lonza (Walkersville, Maryland). Human AD-MSCs were purchased from Invitrogen (Carlsbad, California). These cells were freshly isolated from healthy donors. The c-kit+ stem cell subpopulation was purified from CDCs using a CELLection Pan Mouse IgG Kit and a Dynal MPC-15 magnetic particle concentrator (Invitrogen).
For confirmatory rat studies, 4-month-old Wistar Kyoto rats were used to expand CDCs, BM-MSCs, and AD-MSCs, as described previously (23,28,29). BM-MNCs were also collected from the same rats by using gradient centrifugation (19). Freshly collected BM-MNCs and twice-passaged CDCs, BM-MSCs, and AD-MSCs were used for rat experiments.
Unless otherwise noted, basic Iscove's modified Dulbecco's medium (IMDM) (Invitrogen) supplemented with 10% fetal bovine serum (Thermo Scientific HyClone) and gentamycin 20 mg/ml were used to culture all cell lines.
The identity of CDCs, BM-MSCs, AD-MSCs, and BM-MNCs was investigated using flow cytometry, as described previously (6,8). Briefly, cells were incubated with fluorescein isothiocyanate 7– or phycoerythrin-conjugated antibodies against CD29, CD31, CD34, CD45, CD90, CD105, CD117 (c-kit), and CD133 (eBioscience, Inc., San Diego, California) for 30 min. Isotype-identical antibodies served as negative controls. Quantitative analysis was performed using a CYAN-ADP flow cytometer with Summit 4.3 software (Beckman Coulter, Brea, California) (6,8).
Enzyme-linked immunoadsorbent assay
To compare the potency of the production of growth factors, cells were seeded in 24-well culture plates at densities of 1 × 106/ml (BM-MNCs) or 1 × 105/ml (all other cell types) in fetal bovine serum–free IMDM media (all cell types) for 3 days. The supernatants were collected, and the concentrations of angiopoietin-2, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-1, platelet-derived growth factor, stromal cell–derived factor (SDF)-1, and vascular endothelial growth factor (VEGF) were measured with human enzyme-linked immunoadsorbent assay (ELISA) kits (R&D Systems Inc., Minneapolis, Minnesota), according to the manufacturer's instructions. Given the limited number of rat-specific ELISA kits, we only measured the concentrations of HGF (B-Bridge International, Inc., Cupertino, California), IGF-1, and VEGF in the supernatant with 3 days' culture of rat cells (R&D Systems Inc.).
To compare the production of growth factors from the purified c-kit+ subpopulation and unsorted CDCs, we seeded cells (5 × 104/ml) on 24-well culture plates and culture for 2 days under 20% O2. Growth factors in conditioned media were measured by using ELISA as described earlier.
To determine myogenic differentiation in vitro, cells were seeded on fibronectin-coated, 4-chamber culture slides. After 7 days of culture, cells were fixed, blocked with goat serum for 30 min, and then incubated with mouse anti-human troponin T antibody (R&D Systems Inc.) for human cells or with goat anti-rat troponin T antibody for rat cells. After 1 h of incubation at room temperature, culture slides were washed and then incubated with a phycoerythrin-conjugated secondary antibody. Cell nuclei were stained with 4'-6-diamidino-2-phenylindole. Cardiomyogenic differentiation was quantified by counting positively stained cells.
In vitro angiogenesis assay
Angiogenic potency was assayed by tube formation using a kit (Chemicon International Inc., Temecula, California), according to the manufacturer's instructions. Briefly, cells were seeded on ECMatrix-coated 96-well plates at a density of 2 × 105 cells (BM-MNCs) or 2 × 104 cells (all other cell types) per well. Human umbilical vein endothelial cells were included as positive controls. After 6 h, tube formation was imaged. The total tube length was then measured by using Image-Pro Plus software version 5.1.2 (Media Cybernetics, Inc., Carlsbad, California).
Terminal deoxynucleotidyl transferase dUTP nick end labeling assay
To quantify the resistance to oxidative stress in vitro, cells were seeded on fibronectin-coated, 4-chamber culture slides. After 24 h of culture, cells were cultured with or without the addition of 100 μM H2O2 to the medium for another 24 h. Cells were fixed, and apoptotic cells were detected by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay using the In Situ Cell Death Detection Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. Cell nuclei were stained with 4'-6-diamidino-2-phenylindole; apoptotic cells were counted according to TUNEL-positive nuclei.
Myocardial infarction model and cell implantation
Acute myocardial infarction was created in male SCID-beige mice (10 to 12 weeks old), as described previously (6,8). Briefly, just after ligation of the left anterior descending artery with 9-0 prolene, hearts were injected at 4 points in the infarct border zone with a total of 40 μl of one of the following interventions: phosphate-buffered saline (control, n = 8), 1 × 105 CDCs (n = 20), 1 ×105 BM-MSCs (n = 20), 1 × 105 AD-MSCs (n = 20), 1 × 106 BM-MNCs (high BM-MNCs, n = 11), or 1 × 105 BM-MNCs (low BM-MNCs, n = 9). We studied 2 dosages in BM-MNCs, including one with 10-fold more cells than in the comparator groups, because MNCs are smaller than the other cell types (19) and we did not want to bias against them in terms of total transplanted cell mass.
To compare the c-kit+ stem cell subpopulation purified from CDCs with the unsorted CDCs, we performed a separate study by injecting 1 × 105 purified c-kit+ cells (c-kit+, n = 16) and 1 × 105 unsorted CDCs (unsorted, n = 11) into the infarcted hearts of SCID mice, using the methods described earlier.
Mice underwent echocardiography 3 h (baseline) and 3 weeks after surgery by using the Vevo 770 Imaging System (VisualSonics, Toronto, Ontario, Canada) (8). After the induction of light general anesthesia, the hearts were imaged 2-dimensionally in long-axis views at the level of the greatest left ventricular (LV) diameter. LV end-diastolic volume, LV end-systolic volume, and LV ejection fraction (LVEF) were measured with VisualSonics version 1.3.8 software from 2-dimensional long-axis views taken through the infarcted area. Blinded reading of echocardiography was conducted independently by 2 experienced echocardiographers (K.M. and J.T.). The results correlated well (R2 = 0.66 and 0.73 for baseline and 3 weeks' measurement, respectively) (Online Fig. 1). A Bland-Altman plot indicated the limit of agreement to be from –14.07 to 13.56 (30). Thus, the averages of the 2 readings for LVEF in each mouse were used for statistical analysis.
Mice were sacrificed 3 weeks after treatment. Hearts were sectioned in 5-μm sections and fixed with 4% paraformaldehyde. The engraftment of implanted human cells was identified by immunostaining for human nuclear antigen (HNA; Chemicon International Inc.). To measure cell engraftment, 10 images of the infarct and border zones were selected randomly from each animal. To quantify the apoptotic cells in the heart, slides were fixed and apoptotic cells were detected by TUNEL assay as described earlier. The differentiation of implanted human cells into cardiomyocytes in the infarcted hearts of SCID mice was identified by immunostaining with monoclonal antibodies against human-specific α-sarcomeric actin (α-SA) (Sigma-Aldrich), as described previously (8,31). For morphometric analysis, animals in each group were euthanized at 3 weeks (after cardiac function assessment), and the hearts were harvested and frozen in optimal cutting temperature compound. Sections every 100 μm (5-μm thick) were prepared. Masson's trichrome staining was performed per manufacturer's instructions (HT15 Trichrome Stain [Masson] Kit; Sigma). Images were acquired with a PathScan Enabler IV slide scanner (Advanced Imaging Concepts, Princeton, New Jersey). From the Masson's trichrome-stained images, morphometric parameters (including infarct wall thickness and infarct perimeter) were measured in each section with NIH ImageJ software (8,31).
Quantification of engraftment by real-time polymerase chain reaction
Quantitative polymerase chain reaction (PCR) was performed 3 weeks after cell injection to quantify cell engraftment. Male human cells were injected to enable detection of the SRY gene located on the Y chromosome as a marker of engrafted cells (31). The whole mouse heart was harvested, weighed, and homogenized. The TaqMan assay was used to quantify the number of transplanted cells with the human SRY gene as template (Applied Biosystems, Foster City, California). A standard curve was generated with multiple dilutions of genomic DNA isolated from the injected CDCs to quantify the absolute gene copy numbers. All samples were spiked with equal amounts of genomic DNA from noninjected mouse hearts as a control. For each reaction, 50 ng of genomic DNA was used. Real-time PCR was performed in triplicate with an Applied Biosystems 7900 HT Fast real-time PCR machine. The number of engrafted cells per heart was quantified from the standard curve.
Statistical analysis was performed independently (by H.K.). All results are presented as mean ± SD except as noted. Data sets were first tested for normality (Kolmogorov-Smirnov test) and variance (Levene's test). If both were assured, statistical significance was determined by 1-way analysis of variance followed by post hoc test (SPSS II, SPSS Inc., Chicago, Illinois). If either normality or variance tests failed, nonparametric tests (Kruskal-Wallis test followed by Dunn's post-test) were used. Differences were considered statistically significant when p < 0.05.
Characterization of cell phenotypes
Unlike BM-MNCs, which grow in suspension as small round cells, all other cell types studied (CDCs, BM-MSCs, and AD-MSCs) typically grow as adherent monolayers (Fig. 1A). Flow cytometry distinguished BM-MNCs from other cell types by the predominant expression of pan-hematopoietic marker CD45 (74.7%), compared with <1% in CDCs, BM-MSCs, and AD-MSCs (Fig. 1B). Conversely, >99% of CDCs, BM-MSCs, and AD-MSCs expressed CD105, a transforming growth factor–beta receptor subunit commonly associated with MSCs. However, these 3 cell types can be distinguished by CD90: >99% of BM-MSCs and 85% of AD-MSCs expressed CD90 but only 18% of CDCs did so. CD90 (well known as Thy-1) was originally discovered as a thymocyte antigen (32). In humans, Thy-1 is also expressed by endothelial cells, smooth muscle cells, a subset of CD34+ bone marrow cells, and umbilical cord blood–, fibroblast-, and fetal liver–derived hematopoietic cells. CD90 is widely used as a marker of a variety of stem cells (e.g., MSCs, hepatic stem cells, keratinocyte stem cells, putative endometrial progenitor/stem cells, hematopoietic stem cells) (33,34). On the basis of these findings, CDCs seem to contain a minority of fibroblast and/or weakly committed hematopoietic cells, whereas such populations dominate in the cells of bone marrow and adipose origins. Alternatively, the CD90 in CDCs may simply mark the cardiac mesenchymal subpopulation.
In vitro secretion of growth factors
Increasing evidence supports the generalization that cell therapy boosts cardiac function largely via paracrine mechanisms (25). We thus compared the production of 6 growth factors (angiopoietin-2, bFGF, HGF, IGF-1, SDF-1, and VEGF) by the various cell types. CDCs were unique in their ability to secrete large amounts of all growth factors (Fig. 2A). In contrast, the other cell types failed to express meaningful levels of 1 or more growth factors: BM-MNCs produced little VEGF and SDF-1; BM-MSCs secreted little IGF-1 and bFGF; and AD-MSCs were not rich sources of HGF and SDF-1. Figure 2B depicts schematically the secretion of each of the 6 cytokines in each given cell type, as wheel-and-spoke diagrams in which the length of each spoke is proportional to the growth factor concentration in conditioned media. The symmetrical starburst pattern highlights the relatively high and distributed paracrine factor production of CDCs.
One limitation of our comparison is that we used 10-fold higher concentrations of BM-MNCs in these experiments, with the rationale that these cells are much smaller than the other 3 cell types (24) and thus have a lower secretory biomass. Another limitation of our comparison is the fact that the various human cell types originated from different subjects. To ensure that the findings did not simply reflect donor-specific idiosyncrasies, we compared growth factor secretion by the various cell types derived from individual rats. In agreement with the findings in human stem cells, higher levels of HGF, IGF-1, and VEGF were also observed in media conditioned by rat CDCs than by rat BM-MSCs, AD-MSCs, and BM-MNCs, all collected from the same animals (Online Fig. 2). The well-balanced release of growth factors in vitro confirms the notion that CDCs are particularly rich biological factories (25,35), a feature that may favor enhanced myocardial repair through paracrine mechanisms after implantation into the heart.
Another potential advantage of CDCs is their reported ability to differentiate into cardiomyocytes (8,24,25,31), although this propensity has not been compared quantitatively with other cell types. We therefore examined the ability to undergo spontaneous cardiomyogenic differentiation in vitro by immunostaining for cardiac-specific troponin T. Many human CDCs expressed troponin T (Fig. 3A), in contrast to human BM-MSCs, AD-MSCs, or BM-MNCs, few of which were positive for troponin T. Quantitative analysis revealed that approximately 9% of CDCs expressed troponin T, whereas <1% did so in the other cell types (Fig. 3B). Similar findings were observed using rat CDCs, BM-MSCs, AD-MSCs, and BM-MNCs, all collected from the same animals (Online Fig. 3).
We quantified the angiogenic ability of the various cell types using an in vitro tube-forming assay (36). All cell types could form capillary-like networks on Matrigel (BD Biosciences, Bedford, Massachusetts) within 6 h, with the exception of BM-MNCs (Fig. 3C). Quantitative analysis revealed that the mean tube length of the capillary-like networks was greater in CDCs than in the other cell types (p < 0.05) (Fig. 3D). Thus, CDCs, at least by this simple in vitro assay, are superior in mediating the formation of capillary-like structures.
Resistance to oxidative stress
Enhanced cell resilience to oxidative stress favors transplanted cell engraftment and functional benefit (35). We assayed sensitivity to oxidative stress by exposing cells to H2O2, a powerful oxidant. After 24 h of exposure to 100 μM of H2O2, the number of apoptotic cells tended to be lower in human CDCs than in human BM-MNCs (p = 0.067) (Online Fig. 4), but there was no significant difference among CDCs, BM-MSCs, and AD-MSCs. In rat cells, higher apoptosis was observed in BM-MNCs compared with any of the other 3 cell types after H2O2 exposure (p < 0.05) (Online Fig. 5). Taken together, these data highlight a relative deficiency of BM-MNCs in terms of resistance to oxidative stress.
Cell engraftment and in vivo differentiation
Although most of the benefit of cell therapy is now recognized to be indirect, study after study has revealed a positive correlation between long-term cell engraftment and functional benefit (10,19–22,25). We therefore evaluated the engraftment and differentiation of human cells 3 weeks after direct intramyocardial injection into the infarcted hearts of SCID mice. Consistent with previous reports (7,8,23–25,31), histology results revealed expression of α-SA in some of the surviving progeny of human CDCs (positive for HNA) (Fig. 4A), confirming the cardiomyogenic differentiation in vivo. In contrast, human cells positive for α-SA were observed rarely and inconsistently in mice injected with BM-MSCs, AD-MSCs, and BM-MNCs (data not shown). Quantitative image analysis confirmed that the engraftment (i.e., the numbers of HNA+cells) was greater in mice implanted with human CDCs than with comparator cells (p < 0.05) (Fig. 4B). In addition, the numbers of cardiomyocytes derived from the transplanted cells (HNA+/α-SA+) were greater in mice implanted with human CDCs than with any of the other cell types (p < 0.01) (Fig. 4C). Quantitative PCR confirmed the histological analysis: more human cells were detected in the CDC group than in the low BM-MNC group (p < 0.05) (Fig. 4D) 3 weeks after injection. Also, according to PCR analysis, there was a trend indicating higher engraftment in the CDC group than in the BM-MSC and AD-MSC groups.
In addition to tissue regeneration, tissue preservation may be a salutary component of cell therapy for acute myocardial infarction (25). To evaluate this possibility, we quantified apoptotic nuclei in infarcts of control mice and mice injected with each of the comparator cell types. TUNEL staining revealed apoptotic nuclei in the infarcted hearts 3 weeks after treatment (Figs. 5A and 5B). We counted the total number of apoptotic cells in the infarct and peri-infarct area. The hearts of mice implanted with CDCs exhibited fewer TUNEL-positive cells, compared with all other cell-treated groups (p < 0.05) (Fig. 5C). We speculate that this enhanced tissue preservation may be due to the larger amount of pro-angiogenic and antiapoptotic factors produced by CDCs (19,25,35).
The most meaningful indicator of cell potency, in practice, is the ability to produce functional benefit after transplantation into the injured heart. We measured cardiac function by using echocardiography, and all images were interpreted blindly and independently by 2 experienced echocardiographers. Figure 6 summarizes the results. The LVEF at baseline (i.e., 2 h post-infarction) was comparable, indicating similar ischemic injury among groups. Among the various treatments, the implantation of CDCs resulted in the greatest LEVF at 3 weeks, and it is the only group that was significantly better than the controls (p < 0.05 vs. control). The other cell types, although higher on average than controls, had no clear functional benefit statistically. Echocardiography also revealed smaller end-diastolic and end-systolic LV volumes in the CDC-treated animals (Online Fig. 6).
Potentiating the functional benefits of cell therapy is attenuation of adverse ventricular remodeling (8). To evaluate this process, we examined the morphological consequences of transplantation of the various cell types on myocardial infarct size and wall thinning. Heart morphometry at 3 weeks revealed severe LV chamber dilation and infarct wall thinning in the control hearts (Fig. 7A, Online Fig. 7). In contrast, all the cell-treated groups exhibited attenuated LV remodeling. Compared with controls, the implantation of any type of human cells decreased fractional infarct perimeter and, conversely, increased the minimal infarct wall thickness 3 weeks after treatment (p < 0.05 vs. control group). The protective effect was greatest in the CDC-treated hearts, which had thicker infarcted walls (p < 0.01) (Fig. 7B) but a smaller fractional infarct perimeter (p < 0.05) (Fig. 7C) than any of the other cell-treated groups.
Unsorted CDCs versus the c-kit+–purified cell subpopulation
Having established that CDCs are the most effective cell type among those studied, we moved on to consider how CDCs compare with purified c-kit+ cells. This comparison is germane because c-kit has been argued to identify cardiac stem/progenitor cells (1,7–9), and a purified c-kit+ cardiac-derived cell product is currently being tested clinically. Therefore, in a separate study, we compared unsorted CDCs with equal numbers of c-kit+ stem cells purified from CDCs by using magnetic cell sorting. Purified c-kit+ cells were inferior to unsorted CDCs in terms of functional benefit after transplantation into the infarcted heart, although they did outperform vehicle-injected controls (Fig. 8A). The sorting procedure itself did not compromise cell functional efficacy, as CDCs sorted for CD105 (expressed by >99% of CDCs) exhibited an LVEF comparable to that of unsorted CDCs (data not shown). To investigate one potential mechanism for the functional superiority of CDCs, we measured a variety of paracrine factors in conditioned media from sorted and unsorted cells. Indeed, unsorted CDCs produced higher amounts of paracrine factors in vitro compared with purified c-kit+ cells (Fig. 8B), providing one potential rationale for their enhanced benefit.
By head-to-head direct comparison, we demonstrated a functional superiority of heart-derived cells compared with 3 types of adult stem cells of extracardiac origin: BM-MNCs, and MSCs from bone marrow or adipose tissue. Furthermore, the superiority of CDCs for myocardial repair was consistent with their well-balanced secretion of paracrine factors as well as their higher cardiomyogenic differentiation capacity and engraftment, although further in vivo intervention experiments (e.g., with blocking antibodies) will be required to identify the precise mechanisms of functional superiority.
We selected 4 cell types for comparison that have been used clinically and are considered among the most promising at present for myocardial repair/regeneration. Previous studies (19–22) have shown that the implantation of BM-MNCs, BM-MSCs, and AD-MSCs into the damaged heart can improve cardiac function, likely through paracrine mechanisms, with rare events of myogenic differentiation. Despite the paucity of direct regeneration of new myocardium from these stem cells of extracardiac origin, the improvement of cardiac function reported in previous randomized clinical trials is encouraging (10–18).
One distinctive feature of resident cardiac stem cells is their ability to undergo consistent cardiomyogenic and angiogenic differentiation (1–9,23–25), a finding confirmed here. Although almost 10% of CDCs expressed troponin T in vitro, human CDCs expressing α-SA were infrequently observed in the infarcted hearts of SCID mice 3 weeks after treatment. Furthermore, we did not examine whether these α-SA–positive human CDCs were physiologically integrated with the resident cardiomyocytes of mice. Therefore, regeneration of new functional myocardium directly from the implanted human CDCs is a consistent finding but one of questionable significance. The present evidence supports the notion that mechanism of functional benefit after CDC implantation, as with other cell types, is predominantly dependent on paracrine effects and recruitment of endogenous regeneration (25).
We thus compared the secretion of growth factors that generally are recognized to play critical roles in angiogenesis, antiapoptosis, or cardioprotection. Platelet-derived growth factor was undetectable in media conditioned by any of the 4 cell types, but, beyond even our own expectations, CDCs robustly produced a variety of growth factors, including angiopoietin, bFGF, HGF, IGF-1, SDF-1, and VEGF. Although BM-MSCs, AD-MSCs, and BM-MNCs could produce some of these factors in levels comparable to CDCs, the paracrine profile was uniquely well balanced in CDCs. The robust production of diverse paracrine factors by CDCs provides a potential mechanism underlying their superiority for functional myocardial repair, but further research will be required to understand the precise role of each paracrine factor, as well as the roles of others known to be secreted but not quantified here (37). The use of the same medium (IMDM) for all cell types avoids possible confounding effects due to different culture conditions; nevertheless, the fact that cells were cultured uniformly may minimize favorable features unique to each cell type that might be more apparent with media optimized for each cell type.
Tube formation assays are commonly used to measure the angiogenic potential of endothelial cells (36). The superiority of tube formation observed in CDCs indicates their angiogenic potential, which is in agreement with CDCs' robust secretion of pro-angiogenic cytokines (Fig. 2). The observation that BM-MNCs failed to form any tubes may be due to the fact that MNCs need a longer time (24 h) to form tubes (36), whereas we performed the assay at the 6-h time point. Because we did not stain for endothelial markers (e.g., CD31), it is unknown whether these tube structures actually represent endothelial cells differentiated from the various cell types. Indeed, it has been reported that mesenchymal and fibroblast cells assist in blood vessel formation by aligning into tube networks (38).
We also found CDCs were more resistant to oxidative stress-induced apoptosis in vitro (Online Figs. 4 and 5) and MI-induced apoptosis in vivo (Fig. 5). The superiority of CDCs to other cell types in enhancing host tissue preservation is striking. Therefore, it is conceivable that this action is responsible for the superior impact of CDCs in terms of preserving cardiac function and attenuating pathological remodeling, although the relative importance of the various favorable effects remains to be defined. It should be noted that we assayed apoptosis in vivo 3 weeks after myocardial infarction/cell treatment. At that time point, the acute phase of cell death due to ischemia might have already resolved; therefore, the apoptosis we observed was a reflection of long-term remodeling and heart failure. One limitation of this experiment is that we did not perform double staining for TUNEL- and HNA-positive nuclei. Therefore, we cannot distinguish whether apoptosis is reduced in endogenous cells, transplanted cells, or both. In addition, our results do not exclude the possibility that different levels of inflammatory infiltration among groups might contribute to observed differences in apoptotic rates. Nevertheless, the superior tissue preservation capacity of CDCs is consistent with their robust secretion of antiapoptotic and pro-angiogenic factors.
We did not include a number of other stem cell types in our comparison, including myoblasts and peripheral blood–derived endothelial progenitors, although they have already been tested in clinical trials (17,18). The major reason is the relative lack of enthusiasm in the field for these cell types as candidates for further clinical development for cardiac regeneration (although endothelial progenitors do have positive effects on angina and critical limb ischemia ). We also did not select embryonic stem cell- or induced pluripotent stem cell-derived cardiomyocytes for comparison because they are far from clinical applicability at present, although both may excel in the direct production of new functional myocardium (39,40).
We did, however, compare the therapeutic potency of cardiac progenitor cells purified by virtue of their c-kit-positivity (35,41), relative to unselected CDCs (42). We confirmed the reported ability of c-kit+ cardiac cells to boost cardiac function post-infarction (1,9), but we discovered that c-kit+ cells are not as potent as the CDC mixture either in terms of functional benefit or in paracrine factor secretion. One trivial explanation for this finding would be antibody-related interference with cell potency, but we believe that is unlikely. The c-kit antibody used (43) has been shown to interfere minimally with ligand binding, receptor phosphorylation, and internalization in c-kit–expressing cell lines (44). Also, magnetic-activated cell sorting for mast cells using this c-kit antibody neither induced histamine release nor impaired the ability of cells to release histamine when stimulated (45). We must acknowledge, however, that subtle differences in specific sorting and culture methods for c-kit+ cells may affect the efficacy of the cells. Nevertheless, the finding that the natural CDC mixture is superior to the purified c-kit+ subpopulation adds a new dimension to the emerging notion that mesenchymal cells favor endogenous cardiac regeneration (10,46), at least partly via the attraction of c-kit+ cells. We conjecture that the stromal and mesenchymal cells synergize with the c-kit+ cells in the natural CDC mixture to enhance overall paracrine potency and thereby boost functional benefit; alternatively, c-kit+ cells may be tangential to the mechanism of benefit of CDCs. More experiments are required to flesh out these ideas.
In this first comprehensive head-to-head comparison of 4 different cell types in the same animal model in the same laboratory, with blinded analysis, CDCs were superior in terms of paracrine factor secretion, angiogenesis, cardiomyogenic differentiation, ischemic tissue preservation, antiremodeling effects, and functional benefit. The CDC mixture was more potent than the c-kit+ subpopulation. Ongoing and future clinical studies will serve as the ultimate test of potency, but the present results give good reason for optimism regarding the therapeutic potential of CDCs.
NOTE: A report has appeared of the first clinical trial using cardiosphere-derived cells: Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012 Feb 14 [E-pub ahead of print]; doi:10.1016/S0140-6736(12)60195-0.
For supplemental figures on the study results, please see the online version of this article.
Direct Comparison of Different Stem Cell Types and Subpopulations Reveals Superior Paracrine Potency and Myocardial Repair Efficacy With Cardiosphere-Derived Cells
This study was supported by the National Institutes of Health (HL095203) to Capricor, Inc., by the National Institutes of Health (U54 HL081028) to Dr. E. Marbán, and by the Cedars-Sinai Board of Governors Heart Stem Cell Center. Dr. E. Marbán is the Mark S. Siegel Family Professor of the Cedars-Sinai Medical Center. Dr. E. Marbán and Dr. L. Marbán hold founders' equity in Capricor, Inc. Drs. Smith, Blusztajn, Terrovitis, and L. Marbán are employed by Capricor, Inc. Drs. Malliaras and Terrovitis are consultants of Capricor, Inc.
All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Li, Cheng, and Malliaras contributed equally to this work.
- Abbreviations and Acronyms
- α-sarcomeric actin
- adipose tissue–derived mesenchymal stem cells
- basic fibroblast growth factor
- bone marrow mononuclear cells
- bone marrow–derived mesenchymal stem cells
- cardiosphere-derived cells
- enzyme-linked immunoadsorbent assay
- hepatocyte growth factor
- human nuclear antigen
- insulin-like growth factor
- Iscove's modified Dulbecco's medium
- left ventricular
- left ventricular ejection fraction
- polymerase chain reaction
- severe combined immunodeficiency
- stromal cell–derived factor
- terminal deoxynucleotidyl transferase dUTP nick end labeling
- vascular endothelial growth factor
- Received August 24, 2011.
- Revision received October 19, 2011.
- Accepted November 22, 2011.
- American College of Cardiology Foundation
- Oh H.,
- Bradfute S.B.,
- Gallardo T.D.,
- et al.
- Matsuura K.,
- Nagai T.,
- Nishigaki N.,
- et al.
- Pfister O.,
- Mouquet F.,
- Jain M.,
- et al.
- Messina E.,
- De Angelis L.,
- Frati G.,
- et al.
- Smith R.R.,
- Barile L.,
- Cho H.C.,
- et al.
- Bearzi C.,
- Rota M.,
- Hosoda T.,
- et al.
- Hare J.M.,
- Traverse J.H.,
- Henry T.D.,
- et al.
- Valina C.,
- Pinkernell K.,
- Song Y.H.,
- et al.
- Meyer G.P.,
- Wollert K.C.,
- Lotz J.,
- et al.
- Losordo D.W.,
- Schatz R.A.,
- White C.J.,
- et al.
- Menasché P.,
- Alfieri O.,
- Janssens S.,
- et al.
- Takahashi M.,
- Li T.S.,
- Suzuki R.,
- et al.
- Yoon C.H.,
- Koyanagi M.,
- Iekushi K.,
- et al.
- Gnecchi M.,
- Zhang Z.,
- Ni A.,
- Dzau V.J.
- Johnston P.,
- Sasano T.,
- Mills K.,
- et al.
- Chimenti I.,
- Smith R.R.,
- Li T.S.,
- et al.
- Tang X.L.,
- Rokosh G.,
- Sanganalmath S.K.,
- et al.
- Takahashi M.,
- Suzuki E.,
- Oba S.,
- et al.
- Hahn J.Y.,
- Cho H.J.,
- Kang H.J.,
- et al.
- Cheng K.,
- Li T.S.,
- Malliaras K.,
- Davis D.R.,
- Zhang Y.,
- Marbán E.
- Ades E.W.,
- Zwerner R.K.,
- Acton R.T.,
- Balch C.M.
- He J.Q.,
- Ma Y.,
- Lee Y.,
- Thomson J.A.,
- Kamp T.J.
- Smith R.R.,
- Chimenti I.,
- Marbán E.
- Lerner N.B.,
- Nocka K.H.,
- Cole S.R.,
- et al.